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Cheyne-Stokes respiration is an abnormal breathing pattern which commonly occurs in
patientswith decompensated congestive heart failure and neurologic diseases, inwhom periods
oftachypnea and hyperpnea alternate with periods of apnea. In the majority ofthese patients,
the ventilatory patterns may not be recognized, and the clinical features are generally
dominated by the underlying disease process. Cheyne-Stokes respiration may, however, have
profound effects on the cardiopulmonary system, causing oxygen desaturation, cardiac arrhyth-
mias, and changes in mental status. Treatment ofCheyne-Stokes respiration in congestive heart
failure with supplemental oxygen or nasal continuous positive airway pressure, in addition to
conventional therapy, may improve the overall cardiac function and perhaps the patient's
prognosis.
INTRODUCTION
Cheyne-Stokes respiration (CSR) is aform ofperiodicbreathing inwhichepisodes
of hyperpnea alternate with periods of apnea (Fig. 1). This abnormal respiratory
pattern was originally described in patients with congestive heart failure, first by
Cheyne in 1818 [1] and then by Stokes in 1854 [2]. CSR can occur, however, as a part
ofnormal sleep in healthy individuals and those at high altitude [3,4]. It may also be
present in 20-30 percent of otherwise healthy elderly persons [5,6]. Nevertheless,
when present, itusually indicates the presence ofcongestive heartfailure, neurologic
disease, prematurity, and uremia (Table 1) [7-11].
In this review, we have focused on CSR in congestive heart failure with a search of
literature dating back to the original description ofthe entity by Cheyne and Stokes
in the early and middle 1800s. When congestive heart failure is associated with CSR,
it generally carries a poor prognosis [11]. The apneas are associated with worsening
ofoxygenation and fluctuation in PCO2 and pH, which may have adverse effects on
an already compromised cardiovascular system. Alterations in the breathing pattern
are often difficult to detect clinically, and thus the condition may remain undetected.
The advent of continuous noninvasive ventilatory and oxygenation monitoring
techniques should make the detection of this breathing disturbance easier. This
review covers the literature in English on the subject since 1818 and describes the
pathophysiology of CSR, its associated clinical entities, and its effect on the cardio-
vascular system. We also review the different modalities in the management ofCSR.
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NYHA: New York Heart Association functional class PCWP: pulmonary capillary wedge pressure
REM: rapid eye movement sleep SaO2: arterial oxygen saturation SWS: slow-wave sleep TST: total
sleep time
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FIG. 1. Ninety-two seconds of polygraphic recording during sleep in a patient with
congestive heart failure. Twenty seconds ofcentral apnea characterized by absence ofabdomi-
nal and rib cage efforts and no nasal airflow are followed by28 seconds ofhyperpnea. The cycle
ofapnea-hyperpnea repeats every48 seconds in thispatient. Adecrease in oxygen saturation to
75 percent is present after apnea. R/EOG, L/EOG, right and left electrooculograms,
respectively; EMG, submental electromyogram; EEG, electroencephalogram; SaO2, arterial
oxygen saturation; ECG, electrocardiogram.
TABLE 1
Conditions Associated with Cheyne-Stokes Respiration
Cardiovascular:
Congestive heart failure
Coronary heart disease
Hypertensive cardiovascular disease
Neurologic:
Cerebrovascular disease
Subarachnoid hemorrhage
Trauma
Cerebral tumor
Meningitis
Encephalitis
Narcolepsy
Miscellaneous:
High altitude
Sleep
Prematurity
Elderly status
CO2 narcosis
Uremia
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RESPIRATORY CONTROL SYSTEM IN NORMAL SUBJECTS
It iscurrentlythought that two separate anatomicpathways are responsible forthe
voluntary and the automatic control ofbreathing [12]. In thewaking state, automatic
and behavioral influences interact to establish the level and pattern of breathing.
During sleep, voluntary control is lost, the effects of environmental stimuli are
diminished, and breathing is believed to begoverned almost exclusivelyby automatic
mechanisms. The automatic or metabolic control system consists ofthe chemorecep-
tors (carotid body for hypoxia, and carotid body, aortic body, and central medullary
chemoreceptors for hypercapnia), vagal intrapulmonary receptors, and numerous
brainstem mechanisms that both process information from these peripheral recep-
tors and control the pattern of breathing. This metabolic system keeps ventilation
rhythmic and ensures that the quantity of ventilation occurring at any time is well
matched to the metabolic needs of the body. It is useful to consider the respiratory
control system tobecomposed oftwosubsystems, one forthe regulation ofPCO2 and
the other for P02, that differ in their control characteristics.
Respiratoty Control: CO2 Subsystem
The important role for PCO2 in the maintenance of normal rhythmic ventilation
during sleep has been outlined by Cherniack [13,14]. In the normal state, the
relationship between increasingPCO2 andventilation is linear, and it requires only a
small change from the resting PCO2 level to increase ventilation. The relative
linearity of the ventilatory carbon dioxide response curve tends to keep respiration
stable when hypercapnia is the major respiratory drive. In unconscious subjects,
there is a threshold level ofPCO2 atwhich a type ofbreathingbegins that is not often
seen in fully alert subjects. This threshold for the carbon dioxide effect in breathing
produces an alinearity in the carbon dioxide role and thus acts as a potential source
of instability. Aside from this threshold phenomenon, however, the slope of the
ventilatory carbon dioxide response curve is constant over a wide range of carbon
dioxide tensions.
This arrangement yields a stable ventilatory control system for a number of
reasons. First, hypercapnia is the major respiratory stimulus during sleep, and, as
stated, therelationshipbetweenPCO2andventilation islinear. In addition, there are
relatively large stores of carbon dioxide in the body, such that large increases in
ventilation are necessary to produce changes in PCO2 (a damped system), especially
in the central nervous system where such changes are detected. Figure 2 shows the
ventilatory control system and its components. When there is a change in carbon
dioxide tension level in the blood and tissues, the feedback communication channel
(in this case, the circulation) transports the blood to the carotid, aortic, and
medullary chemoreceptors. These receptors detect the difference between the
current values and the normal values ofblood gas tension and relay this information
electrically to the respiratory neurons in the brainstem (the controller). The nor-
mally operating carbon dioxide controller (a proportional controller) increases
ventilation by two to four liters per minute for each millimeter rise in arterial carbon
dioxide tension. This linear relation persists over a wide range of carbon dioxide
tensions, indicating a constant controller gain (see Fig. 2). Impulses are sent via
intercostal and phrenic nerves (neural output) to respiratory muscles that adjust the
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ventilation so as to minimize changes inbodygas content andblood gas tensions. The
cycle continues until a steady state is reached.
Respiratory Control: 02 Subsystem
In contrast to the carbon dioxide control system, the hypoxic response is neither
linear nor damped. Changes in P02 in the normal range have little influence on
ventilation (Fig. 2). Since the relationship between hypoxia and ventilation is nearly
hyperbolic, however, increases in controller gain (the slope ofP02ventilation curve)
for P02 occur continuously and at an increasingly greater rate as hypoxia becomes
more severe. This process tends to destabilize breathing when hypoxia becomes the
major respiratory drive and couldyield apnea or periodicbreathing [10,15,16].
The ratio of the volume of gas (oxygen) stored in the body to change in gas
(oxygen) tension (e.g., P02) is a measure ofthe distensibility ofthe system; the more
gas stored for a given change in gas tension, the more the distensibility and,
therefore, the greater the damping. The body oxygen stores (lung gas and blood
oxygen content) are minute compared with the carbon dioxide stores. This fact
results in underdamping or decrease in the distensibility of oxygen stores, hence
greater fluctuation ofP02 around the normal range. The combination ofa nonlinear
controllergain and anunderdamped systemcould lead to anunstable control system,
where P02 and PCO2 fluctuate widely around the mean values [17]. This condition
results inthe development ofapnea and hyperpnea in the formofperiodicbreathing.
CONTROL OF VENTILATION DURING SLEEP
More recent studies have confirmed a prominent role played by PCO2 in the
maintenance ofrhythmic breathing during sleep. Skatrud and Dempsey [18] showed
that, with passive positive-pressure hyperventilation of sleeping subjects, apnea
could be produced by a reduction in PCO2 ofonly 3-6 torr below the sleepingvalue;
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the actual PCO2 level associated with apnea might only be 1-2 torr below the awake
values. Each individual seemed to have an "apnea threshold" PCO2 level, below
which apnea was commonly seen. Therefore, the waking PCO2 level was at or near
this apnea threshold, so that the waking PCO2 level may be inadequate to stimulate
ventilation during sleep. It was also demonstrated that periodic breathing during
sleep, which is frequently seen during prolonged hypoxia, could be abolished by
elevating the PCO2 above the predetermined apnea threshold. This finding suggests
that hypopnea induced by hypoxia, not hypoxia itself, is the pivotal element in such
periodic breathing. These studies suggest that ventilation is remarkably dependent
on the metabolic control system during sleep, and that the primary stimulus to
respiration during sleep may be arterial PCO2. If the PCO2 drops below a certain
level ("apnea threshold"), breathing is likely to become dysrhythmic whether
hypoxia is present or not. This drop may partly explain the dysrhythmic breathing
frequently seen at sleep onset. As an individual changes from wakefulness to stage 1
or 2 sleep, the PCO2 level that was adequate to stimulate ventilation during
wakefulness may be inadequate to do so during sleep when an apnea occurs [16].
This apnea may arouse an individual, and the process may repeat itself. Once a stable
sleep stage is reached, ventilation should become rhythmic under metabolic control.
Any disease process that adversely affects this metabolic ventilatory control system
could, however, lead to unstable or periodic breathing during sleep. An individual
with such a problem may breathe adequately during wakefulness when the behav-
ioral influences on respiration are playing an important role.
ALTERED RESPIRATORY CONTROL SYSTEM AND CHEYNE-STOKES
RESPIRATION
CSR is an instability in the ventilatory control system in which circulation time,
controller gain, and the damping characteristics of the oxygen and carbon dioxide
stores play an important part [15,17,19]. In the respiratory system, circulation time
corresponds to delays in information transfer, and the controller gain corresponds to
the slopes of the curves relating ventilationto PCO2 and P02. Damping is affected by
the dynamic characteristics of the body's gas stores (oxygen and carbon dioxide in the
lung, dissolved in body fluids, and in chemical combination).
Four major theories have been advanced to explain periodic breathing: (1) That
CSR can occur in a normal person when circumstances increase the influence of
oxygen control on ventilation and decrease that of carbon dioxide by producing
hypoxia and hypocapnia simultaneously, such as occurs at high altitude and in
persons with cerebrovascular disease causing depression of carbon dioxide respon-
siveness. (2) That CSR is due to removal of inhibiting cortical influences by disease
or medications, which may increase the gain of the carbon dioxide receptors,
increasing the propensity for instability; this state could occur in the setting of
cerebrovascular disease, anesthesia, use of sedatives, and use of morphine. (3) That
CSR is due to underdamping of the system, as in pulmonary congestion, where lung
volumes are decreased and the ability to store carbon dioxide and oxygen in the
functional residual capacity is diminished. (4) That CSR is due to prolonged
circulation time with delay in feedback loop; this theory explains why alveolar and
arterial gas tensions are out of phase during CSR. Arterial carbon dioxide tends to be
highest and oxygen lowest during hyperpnea, whereas the reverse is true of alveolar
gas levels. Prolonging the circulation time or delay in the feedback loop may be one
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of the explanations for CSR occurring in patients with congestive heart failure. This
idea was first postulated by Pembrey in 1908 [20] and later demonstrated by Guyton
et al. in anesthetized dogs with prolonged circulation time [21]. It is thought that,
with delayed circulation, the receptors (carotidbody andmedullarychemoreceptors)
would not be exposed to fluctuations in blood gas levels until hypoxemia has already
occurred. Because ofthis delayed response, the abnormalities inblood gas levels may
be amplified. Because ofthis amplified input, the response is increased and, because
of the increased circulation time, the normal end point will not be reached and an
overcorrection will be achieved. This process promotes a cycle which results in
hypercapnia on one end ofthe spectrum and hypocapnia on the other. Guyton et al.
[21] artifically prolonged the circulation time in dogs and achieved CSR; they
prolonged the circulation time by two to five minutes and bypassed the normal
circulation to the brain. There was no data on the neurologic function of these dogs
and whether this condition also may have played a role in the CSR. The circulation
time in congestive heart failure is usually prolonged, but not to this degree. Brown
and Pluminvestigated 28patients, five ofwhomwere freeofcardiacdisease [7]. They
measured circulation time by an ear oximeter adjusted to respond to methylene blue.
These investigators found that the circulation time was prolonged in patients with
CSR, compared to a control group. They also found that circulation time was
prolonged in patients with congestive heart failure but without CSR. In some of the
patients with CSR, they demonstrated a normal circulation time. These studies
suggest that a delay in the circulation time may play a role, along with other factors,
in promoting CSR, but that is not in and ofitselfthe pathogenetic mechanism.
Increase in oxygen controller gain (increasing the hypoxic ventilatory response)
was demonstrated to yield periodic breathing by Chapman et al. [16] in a group of
normal subjectswhen theywere exposed tovarious levelsofhypoxia. This increase in
controller gain of the system magnifies the effects of chemical responses on the
minute ventilation, yielding a lower PCO2, which may lead to apnea. Hypoxemia,
which is commonly present in pulmonary edema and congestive heart failure, tends
to increase sensitivity to hypoxia and carbon dioxide levels.
Another possible mechanism, which works in conjunction with the hypoxic re-
sponse aswell as the delayed feedback loop, is a shift in the CO2ventilatory response
curve to the right. This rightward shift theoretically can increase the CO2 threshold
before a respiratory response is initiated. Cooling the ventral surface ofthe medulla
in cats caused blunting of the CO2 response curve, which resulted in periodic
breathing [17]. In man, metabolic alkalosis or sleep tends to shift the CO2 response
curve to the right.
In summary, there are several mechanisms responsible for the generation ofCSR.
The pathophysiology lies in a combination ofmechanisms, some ofwhich have been
described above. In patients with congestive heart failure, there is an instability in
respiratory drive due to underdamping of the system (decreased functional residual
capacity is often seen in patients with congestive heart failure), delayed feedback
loop (prolonged circulation time), and increased controller gain due to hypoxia and
hypocapnea.
CLINICAL FEATURES ASSOCIATED WITH CHEYNE-STOKES
RESPIRATION
The clinical features associated with CSR have been categorized according to the
phase of respiration, hyperpnea or apnea (refer to Table 2). Arrhythmias are
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TABLE 2
Physiological Changes During Cheyne-Stokes Respiration
Physiologic Parameters Hyperpnea Apnea
P02 4
PCO2 4
Heart rate ; Heart block
Cardiac output t 4
Cerebral blood flow 4
Reflexes 4
Sensorium Awake, agitated Somnolent, stuporous
commonly observed duringthe apneic phase ofCSR. Cardiac arrhythmias have been
described in as many as 20 percent of patients with CSR and include sinus
bradycardia, heart blocks, atrioventricular dissociation, ventricular ectopic beats,
ventricular tachycardia, and ventricular asystole with Stokes-Adams attacks. It is
believed that perhaps increased vagal discharge during the apneic phase may be
important in thepathogenesis ofthese arrhythmias. Othercontributing factors to the
increased incidence of arrhythmias include the presence of underlying cardiac
disease and heart failure, use of digoxin, and electrolyte disturbances and hypoxia.
During the apneic phase, the cerebral blood flow is increased. This increase is in
response to an elevation in the PCO2, resulting in cerebral vasodilation. The sensory
reflexes are depressed during apnea when the arterial oxygen saturation is high and
the arterial CO2 tension and cerebral blood flow are low. In contrast, the hyperpneic
phase is often accompaniedbyrestlessness, agitation, muscle twitching, and hyperre-
flexia with occasional arousals and awakenings.
The association ofCSRwithcongestive heartfailurewasfirst notedbyCheyne and
Stokes [1,2] and then later by Harrison et al. [22]. The incidence of CSR appears to
be quite high in patientswith decompensated leftventricularfunction, being present
in40-100 percent ofpatients (refer toTable3). Findleyet al. [11] studied 15 patients
with leftventricular heart failurewithout knownbreathing disorders. All thepatients
were dyspneic at rest and rated New York Heart Association (NYHA) functional
class III or IV (dyspnea at rest or with minimal exertion). On polysomnography, six
of the 15 patients (40 percent) exhibited CSR with five or more central apneas per
hour of sleep. The authors also examined the relationship between CSR and
short-term mortality in this group of patients. Remarkably, 100 percent of the
TABLE 3
Prevalence ofCheyne-Stokes Respiration (CSR) in Patients with Congestive Heart Failure
Study No. ofPatient NYHAa Class Patients with CSR (%)
Findley et al. 15 III-IV 6/15 (40)
1985 [11]
Dark et al. 6 N/A 5/6 (83)
1987 [23]
Hanley et al. 10 III-IV 10/10 (100)
1989 [25]
aNYHA, New York Heart Association functional class ofcongestive heart failure
In these studies, Cheyne-Stokes respiration was documented by polysomnographic method in patients
with decompensated left heart failure.
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TABLE 4
Cheyne-Stokes Respiration in Congestive Heart Failure Pre- and Post-Medical Therapy
Central Apnea Hypopnea SaO2/ < 85% (minute)
Age
Patient (years) Pre Post Pre Post Pre Post
1 62 230a 42a 19 9 139 1
2 73 7a 2a 109 0 52 0
3 46 50 0 48 0 0 0
4 59 17a 0 82 14 7 0
5 76 54a 84 6 2 12 N/Ab
6 44 241a 229a 26 33 46 60
aDenotes Cheyne-Stokes respiration
bNot available
cSaO2, arterial oxygen saturation
Adapted from [23]
patients with CSR died within the following six months, whereas only 33 percent of
the remaining patients without CSR died within the same period. Dark and col-
leagues [23] performed polysomnography within thefirst 48 hours ofadmission ofsix
patients with decompensated left ventricular failure. A second studywas performed
aftermedical treatment priortotheirdischarge. Noneofthesepatientswasknown to
have breathing abnormalities prior to their admissions. They found that all patients
during the initial sleep study had abnormal breathing patterns. The respiratory
disturbances were predominantly central apneas, followed by hypopneas and, less
frequently, by obstructive and mixed apneas. Five of the six patients (83 percent)
exhibited CSR. Three ofthese five patients had severe andprolonged arterial oxygen
desaturations. Following medical therapy, which included ionotropic agents, diuret-
ics, and oxygen, and once judged clinically compensated, all patients underwent
repeated polysomnography without supplemental oxygen. The researchers found a
significant decrease in the number of sleep disturbances as well as improvement in
oxygenation followingmedical therapy (refertoTable4). Onepatientwhocontinued
to dopoorly despitevigorous treatment underwent cardiac transplantation. Arepeat
polysomnography performed one month aftertransplantation showed no evidenceof
breathing abnormalities, and previously noted severe desaturation was no longer
present.
Hanly et al. evaluated ten patientswith stable and "maximally" treated congestive
heartfailure forrespiratory disturbances duringsleep [24]. All ofthesepatientswere
NYHA III or IV andwere not known to have abnormal breathing during sleep prior
to enrollment in this study. On polysomnography, CSRwas found in all patients and
occurredpredominantly during stage 1 and 2 non-REM (rapid eye movement) sleep.
Arterial oxygenation was normal during wakefulness; however, significant hypox-
emia developed during sleep as a consequence of CSR. Sleep was disrupted in all
patients secondary to frequent arousals, which occurred during the hyperpneic
phase. The predominance of CSR occurring during non-REM sleep reflects the
difference in respiratory control between non-REM and REM sleep. Theventilatory
responses to hypoxia and hypercapnia are less during REM sleep, and hence there is
more stability in the control system. This study further illustrated that, in this group
ofhigh-risk patients, awake oxygen saturation did not correlate with oxygen satura-
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tion during sleep. Severe hypoxemia can adversely affect an already compromised
cardiovascular system and may contribute to increased mortality of these patients.
Moreover, the neuropsychiatric consequence of impaired sleep needs to be consid-
ered in the rehabilitation ofthese patients.
TREATMENT
The treatment of CSR in congestive heart failure, much like its incidence and
pathogenesis, remains to be clarified. In addition to standard medical treatment of
congestive heart failure with ionotropic agents, diuretics, and preload and afterload
reducing agents, however, other modalities such as oxygen, positive-pressure breath-
ing, and theophylline may prove effective as adjunct treatment modalities.
Oxygen
As described, Dark et al. found a significant improvement in the number of
respiratory disturbances as well as in oxygenation following aggressive medical
therapy [23]. They did not comment on improvement in functional class or survival,
however. Hanly et al. [25] investigated the effects of oxygen therapy versus com-
pressed air in patients with CSR and congestive heart failure. They found a
significant reduction in the amount ofCSR as a percentage oftotal sleep time in the
oxygen-treated groups versus the compressed air-treated groups, while no change
was made in medical therapy in either group. They also found that oxygen corrected
nocturnal hypoxemia and improved sleep (see Fig. 3). Again, improvement in clinical
status and survival were not evaluated.
Nasal Continuous PositiveAirway Pressure (Nasal CPAP)
The efficacy ofnasal continuous positive airway pressure (CPAP) in central apnea
has been previously documented [26]. Takasaki et al. [27] evaluated the effects of
nasal CPAP in patients with chronic stable congestive heart failure who demon-
strated CSR during sleep. They evaluated five patients who were NYHA class III or
IV. All patients treated with nasal CPAP showed marked improvements in apnea
index, as well as improved nocturnal oxygenation (refer to Table 5). The cardiac
status improved in all patients while on nasal CPAP for seven to 23 months of
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TABLE 5
Cheyne-Stokes Respiration in Congestive Heart Failure: Effect ofNasal CPAPa
Variable Condition Group Data p Value
Apneas Control 60 ± 12
No./hours of sleep CPAP 9 ± 7 <0.01
Apnea time Control 44 ± 8
% ofTSTV CPAP 5 ± 4 <0.01
Apneas plus hypopneas Control 69 ± 9
No./hours ofsleep CPAP 15 ± 7 <0.005
Mean low nocturnal Control 84 ± 3
SaO2/ CPAP 91 ± 5 <0.025
aCPAP, continuous positive airway pressure
bTST, total sleep time
cSaO2, arterial oxygen saturation
Data are expressed as the mean ± SE. Statistical analyses are by paired t tests.
Adapted from[27]
follow-up. All patients showed marked improvement in exercise tolerance as well as
improvement in theirfunctional class, fromNYHAclass III or IVto class II,while no
change was made in their cardiac medications during this time.
Patients with congestive heart failure have a reduction in their functional residual
capacity as well as oxygen and carbon dioxide stores. Nasal CPAP increases the lung
volume by recruiting alveoli and increasing the lung oxygen store. Another mecha-
nism by which nasal CPAP may help these patients is its effect on left ventricular
function [28]. Positive intrathoracic pressure causes a reduction in the preload, as
well as a reduction in afterload, by decreasing left ventricular transmural pressure.
As a result, leftventricular ejection fraction may increase with concomitant decrease
in circulation time. In a recent study, nasal CPAP at a level of5 cmH20 pressure in a
group of patients with congestive heart failure and elevated pulmonary capillary
wedge pressure (PCWP) of 19 + 3 mmHg resulted in a 17 percent increase in cardiac
index and a 10 percent decrease in PCWP [29]. Nasal CPAP had no effect on cardiac
hemodynamics in patients with normal PCWP.
Taken together, these data suggest that nasal CPAP and oxygen might prove
efficacious in the treatment ofpatientswithsymptomaticcongestive heartfailure and
CSR.
Theophylline
Aminophylline has been reported to be effective in the treatment of CSR [30-32]
and central apneas [33,34]. In a more recent study on five patients with CSR (two of
whom had congestive heart failure, NYHA class III), theophylline significantly
decreased the CSR, while it produced no change in non-CSR breathing disorder
[35]. The drawback oftheophylline in the treatment ofCSR is that it might increase
arousals and cause sleep fragmentation. In the aforementioned [35] study, however,
theophylline actually decreased the sleep disruption and fragmentation because the
majority ofdisordered-breathing eventswere responsive to theophylline.
The mechanism by which theophylline ameliorates CSR is unknown at present.
Two possible mechanisms have been proposed [35]: (1) Theophylline has a car-
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diotonic effect and may increase cardiac output and decrease circulation time in
patients with heart disease. (2) Reversal of hypoxic ventilatory depression is medi-
ated through inhibition of adenosine receptors [36,37]. Further studies are needed,
however, to determine ifthese mechanisms ofaction oftheophylline are therapeuti-
cally important in the treatment ofCSR.
In conclusion, although CSR in patients with congestive heart failure is a well-
described entity, this breathing abnormality and its clinical consequences often go
unrecognized. The true incidence of CSR in patients with severe congestive heart
failure is unknown, although, from the studies described, it appears to be common
and the clinical implications undesirable. Patients with stable NYHA class III or IV
heart failure or patients who are repeatedly admitted for decompensated heart
failure, despite maximal medical therapy, may benefit from sleep investigation.
Nocturnal oximetry may identifypatients with a significant cyclical pattern ofoxygen
desaturations. This subgroup ofpatients should undergo polysomnography to define
better the sleep architecture, sleep efficiency, and to characterize the respiratory
disturbances. Patients who exhibit CSRwith severe oxygen desaturation maybenefit
from treatment. If medical management of their underlying heart failure is not
already maximized, then this action would be the first step of therapy. Nocturnal
oxygen, at least in the small studies discussed, has been shown to be ofbenefit in this
patient population. Nasal CPAP, as described, may benefit these patients by increas-
ing left ventricular ejection fraction and improving their functional class.
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